Compare Ascendis Pharma A/S (ASND) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Wynn Resorts, Limited — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Wynn Resorts, Limited trades at $99.4 (market cap $10.35B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WYNN | |
|---|---|---|
Market Cap | $17.74B | $10.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $133.34 |
52-Week Low | $163.32 | $94.78 |
Enterprise Value | $18.11B | $20.72B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Wynn Resorts (WYNN) trades at $99.77, up 0.95% on the day, but remains 13.4% down year-to-date amid bearish technical signals. The company reported Q1 2026 EPS of $1.25, meeting expectations, but has missed estimates in three of the last four quarters. Revenue growth continues with $7.14B in 2025, though net margins have compressed from 11.17% in 2023 to 4.58% in 2025. High debt levels persist with $10.50B long-term debt, while analyst consensus remains strongly bullish with a $134.60 price target.
The outlook is mixed: strong analyst support and luxury market positioning offer upside potential, but margin pressure, high leverage, and recent earnings misses present significant risks. The stock's current valuation at 28.59 P/E appears stretched given declining profitability, making execution on future growth critical for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
